CClinicalTrials.gg
Enrolling by invitationNCT07606053no existUpdated May 26, 2026

The Role of the Physiological Endometrial Microbiota in Assisted Reproduction Outcomes

An observational study in Repeated IVF Failure and Microbiota, sponsored by Assisting Nature. Enrolling by invitation at 1 site in Greece. Open to female participants aged 18 Years to 54 Years. Per ClinicalTrials.gov, last updated 2026-05-26.

Sponsored by Assisting Nature · Observational

From the registry’s dates

  • Primary completion was expected by May 2026, 4 months ago, but the record still lists the study as enrolling by invitation.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
80
Ages
18 Years to 54 Years
Sex
Female
01

Study summary

The goal of this observational study is to investigate the influence and contribution of the normal composition and balance of the endometrial microbiota on the achievement of embryo implantation and the maintenance of pregnancy in women undergoing IVF, with comparable clinical profiles, including patients with a history of RIF or RPL, evaluated under identical treatment protocols and hormonal conditions.

The main questions it aims to answer are:

  1. Does the normal composition of the endometrial microbiota, particularly the dominance of Lactobacillus species, influence embryo implantation success in women undergoing IVF?
  2. Does the endometrial microbiota profile affect pregnancy maintenance, ongoing pregnancies, and live birth rates in women with a history of recurrent implantation failure (RIF) or recurrent pregnancy loss (RPL)

Participants will not undergo any additional interventions beyond standard clinical care.They will provide clinical data already collected as part of routine IVF procedures.

Read the detailed description

Endometrial biopsies were collected from patients using a Pipelle catheter during the designated phase of the menstrual cycle. Each sample was immediately placed in a specialized preservative solution and transported to two external laboratories for analysis.

In the first laboratory, bacterial DNA was extracted using a CE-IVD kit, followed by targeted amplification and barcoded sequencing of seven hypervariable regions (V2, V3, V4, V6, V7, V8, V9) of the 16S rRNA gene using the 16STM metagenomic kit and Ion Torrent sequencing system (Ion GeneStudio S5 with Ion Chef Instrument). Data were analyzed with Ion Reporter™ software and MicroSEC ID, using MicroSEC ID and Greengenes databases for taxonomic classification.

In the second laboratory, total DNA was extracted, and targeted amplification of the 16S rRNA gene was performed using the 16S Barcoding Kit 24 V14 (Nanopore), followed by NGS on the MinION Mk1C analyzer. Bioinformatic analysis was conducted using the EPI2ME Labs 16S workflow. Bacterial composition was classified at the genus level, with results expressed as relative abundance percentages. OTU-level data were not disclosed.

Interpretation of microbiota profiles was performed by the treating physician or clinical geneticist. Patients whose samples showed decreased Lactobacillus abundance or the presence of potentially pathogenic microorganisms received individualized interventions. These interventions included a two-week course of antibiotics tailored to the patient's clinical history, followed by probiotics administered orally or via combined oral and vaginal routes for two weeks to two months. Antifungal agents were administered when clinically indicated.

Embryo transfer schedules were adapted based on microbial profiles and clinical assessment. Patients with normal microbial profiles proceeded with IVF in the next cycle. Patients with abnormal profiles, signs of inflammation, or potential pathogenic colonization had embryo transfer postponed for at least one month following completion of the therapeutic regimen.

The study provides a detailed methodological framework for endometrial microbiota analysis, including sample collection, DNA extraction, sequencing strategies, bioinformatic pipelines, and clinical decision-making based on microbial composition, aiming to support personalized management in assisted reproduction.

02

Conditions studied

  • Repeated IVF Failure
  • Microbiota

Keywords

  • Physiological Endometrial Microbiota
  • Endometrial Microbiota
  • IVF
  • In vitro fertilization
  • Assisted reproduction
  • Implantation success
  • Embryo
  • Endometrial Microbiome
  • Microbiota
  • Microbiome
03

In context

Lead sponsor

Assisting Nature is the lead sponsor of 10 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 54 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants were required to be between 18 and 54 years of age, in accordance with the legally permitted age limits for embryo transfer in Greece

Inclusion criteria

  1. Individuals who are biologically female.
  2. Age between 18 and 54 years, in accordance with the legally permitted age limits for embryo transfer in Greece.
  3. Undergoing in vitro fertilization (IVF) treatment.
  4. Clinical history consistent with recurrent implantation failure (RIF) or recurrent pregnancy loss (RPL) and comparable IVF treatment profiles.
  5. Ability to provide informed consent for the use of clinical and microbiome data for research purposes

Exclusion criteria

Exclusion Criteria:

  1. Individuals who are not biologically female.
  2. Age below 18 or above 54 years.
  3. Absence of endometrial biopsy samples or incomplete clinical data.
  4. Presence of significant uterine abnormalities or medical conditions that contraindicate embryo transfer.
  5. Participation in another interventional clinical study that may interfere with microbiome assessment or IVF outcomes.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
80 participants (estimated)
Target follow-up
3 Months
Patient registry
Yes

Groups and cohorts

  • Lactobacillus-dominant microbiota

    Participants whose endometrial microbiota is dominated by Lactobacillus species. Data were collected from previously obtained endometrial biopsies, analyzed via 16S rRNA gene sequencing. No interventions were performed beyond standard IVF clinical care.

  • Non-Lactobacillus-dominant microbiota

    Participants whose endometrial microbiota shows depletion of Lactobacillus species or presence of potentially pathogenic microorganisms. Data were collected from previously obtained endometrial biopsies, analyzed via 16S rRNA gene sequencing. In some cases, participants received individualized clinical interventions (e.g., antibiotics or probiotics) based on their microbial profile as part of routine care.

06

What researchers measure

Primary outcomes

  1. Implantation Rate according to microbiome profile

    The study formally assesses differences in embryo implantation rates between women with Lactobacillus-dominant and non-Lactobacillus-dominant endometrial microbiota profiles.

    Time frame: From the day of the embryo transfer to the day of confirmation of implantation (2-4 weeks)

  2. Ongoing Pregnancy/Live Birth Rate according to microbiome profile

    Association between endometrial microbiota composition and the likelihood of achieving an ongoing pregnancy or live birth

    Time frame: From the day of embryo transfer up to the end of the first trimester (up to 12 weeks of gestation) and live birth until delivery (up to 40 weeks of gestation)

  3. Biochemical pregnancy rate and microbiome status

    Rate of biochemical pregnancies in relation to endometrial microbiota profile

    Time frame: From the day of embryo transfer to the day of confirmation of implantation (2-4 weeks)

Secondary outcomes

  1. Endometrial microbiota composition

    Relative abundance of Lactobacillus versus non-Lactobacillus genera in endometrial biopsies analyzed by 16S rRNA sequencing.

    Time frame: At time of biopsy collection (during procedure)

07

Study locations

1 site
  • Assisting Nature
    Thessaloniki, Greece
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07606053
Lead sponsor
Assisting Nature
Responsible party
Sponsor
First posted
May 26, 2026
Start date
Jan 2, 2025
Primary completion
May 30, 2026 (estimated)
Completion
Jun 25, 2026 (estimated)
Last update
May 26, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion